TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02573350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBR
Description: Selection and administration of the treatment medications (i.e. OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study investigators could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBR
Description: Selection and administration of the treatment medications (i.e. OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study investigators could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
Study: NCT01811160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: A capsule of melatonin was administered nightly (20:00hrs).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules were administered at 20:00hrs for eight weeks
Study: NCT00958152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCH-222
Description: Capsules, Oral, 400 mg, q12h, Days 1-10 and Days 28-37

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCH-222
Description: Capsules, Oral, 750 mg, q12h, Days 1-10 and Days 28-37
Study: NCT04511455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib 60 mg/day peroral
Study: NCT04164472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Friend to Friend (F2F) with Coaching
Description: Friend to Friend (F2F) with Coaching has 14 small group sessions and 8 classroom sessions as led by school staff with coaching from the Children's Hospital of Philadelphia (CHOP) research team. The program aims to improve problem solving and prosocial behaviors, and decrease aggressive behaviors.
Study: NCT00958152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCH-222
Description: Capsules, Oral, 1000 mg, q12h, Days 1-10 and Days 28-37

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: Tablet, Oral, 1125 mg, q12h, Days 18-37

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: Tablet, Oral, 1125 mg, q12h, Days 18-37
Study: NCT02083718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PBSC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs
Study: NCT03456453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIDA Standard for HIV Prevention
Description: The NIDA Standard is a manualized, HIV prevention education intervention focused on reducing risky sexual and drug use practices. It will be adapted for Facebook in this pilot trial.
Study: NCT04960033

Intervention type: BEHAVIORAL
Intervention: FRAX
Description: The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was ≥20% or the 10-year probability of HF was ≥3%.
Study: NCT00958152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: Tablet, Oral, 1125 mg, q12h, Days 18-37
Study: NCT04579705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Using a brush
Description: Surgical hand scrubbing will be performed in 1 minute and 2 minutes using a disposable nail brush.
Study: NCT01741363

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIT(Eiken OC-Sensor) Two-year interval
Description: Screening with two-year interval

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIT(Eiken OC-Sensor) Two-year interval
Description: Screening with two-year interval

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HpSA (Firstep Helicobacter pylori Antigen Rapid Test)
Description: HpSA for detection of upper gastrointestinal diseases; screen and treat for H. pylori infection. Upper endoscopy for H. pylori carriers. HPSA+FIT compared with FIT alone.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIT only
Description: HPSA+FIT compared with FIT alone.
Study: NCT01218490

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovarian cancer surgery
Study: NCT01782846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixprim®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dafalgan-Codeine®
Study: NCT03049319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Psoriashield in the presence of a non-UV absorbing block.
Description: The psoriashield will be applied to patient's back in the presence of a non-UV absorbing block.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Psoriashield in the presence of a UV absorbing block.
Description: The psoriashield will be applied to patient's back in the presence of a UV absorbing block.
Study: NCT03049319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Psoriashield
Description: The psoriashield will be applied to patient's back.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xtrac laser in the presence of a non-UV absorbing block.
Description: The Xtrac laser will be applied to patient's back in the presence of a UV absorbing block.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xtrac in the presence of a UV absorbing block.
Description: The Xtrac laser will be applied to patient's back in the presence of a non-UV absorbing block.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xtrac laser
Description: The Xtrac laser will be applied to patient's back.
Study: NCT01850251

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement with HMB and vitamin D
Description: High protein, high calorie nutritional supplement enriched with hydroxymethylbutyrate and vitamin D.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard nutritional supplement
Description: High protein, high calorie nutritional supplement.
Study: NCT01915758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clindamycin1%/tretinoin 0.025% gel
Description: clindamycin1%/tretinoin 0.025% gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle gel
Description: vehicle gel
Study: NCT01197144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Subcutaneous, 40 mg every other week for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous, every other week for 4 weeks
Study: NCT02333825

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Medial patellofemoral ligament reconstruction surgery
Description: Medial patellofemoral ligament reconstruction surgery using hamstring autograft

Intervention type: OTHER
Group type: OTHER
Intervention: Physical therapy and rehabilitation
Description: A standardized physical therapy and rehabilitation program to be administered and guided by rehab specialists
Study: NCT04715828

Intervention type: OTHER
Intervention: Cryopreserved semen
Description: sperm will be frozen in Cryosperm® cryoprotectant medium (Origio). The samples will be packaged in previously identified high security straws (Cryobiosystem). Slow freezing of the straws will be carried out using the Nanodigicool® programmable device (Cryobiosystem).

Intervention type: OTHER
Intervention: Cryopreserved semen
Description: sperm will be frozen in Cryosperm® cryoprotectant medium (Origio). The samples will be packaged in previously identified high security straws (Cryobiosystem). Slow freezing of the straws will be carried out using the Nanodigicool® programmable device (Cryobiosystem).

Intervention type: OTHER
Intervention: Acute and low irradiation
Description: sperm sample will be placed on the scanner's processing table to be exposed for 1 to 2 seconds. Several dose levels will then be made in order to limit the value of 17 mGy

Intervention type: OTHER
Intervention: Long and low irradiation
Description: sperm sample will be exposed to gamma radiation by adding a solution of Tc99m for 3 hours.

Intervention type: OTHER
Intervention: Long and medium irradiation
Description: sperm sample will be exposed to gamma radiation by adding a solution of I131 for 3 hours
Study: NCT01253694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of 0.5 mg of Intravitreal Ranibizumab
Description: Following the sterile technique, intravitreal injection of anti-VEGF is applied

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of 0.5 mg of Intravitreal Ranibizumab
Description: Following the sterile technique, intravitreal injection of anti-VEGF is applied
Study: NCT01981031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone® Combo
Description: Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog® Mix25
Description: Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
Study: NCT01577524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: Subjects in the treatment group will receive 3.5% diluted Povidone Iodine solution in the surgical incision in a quantity sufficient to fill the wound to the level of the skin. The Povidone Iodine solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with normal saline solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subjects in the Placebo Comparator group will receive normal saline solution in a quantity sufficient to fill the wound to the level of the skin. The saline solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with additional saline solution to replicate the saline wash procedure followed in the Treatment group.
Study: NCT02845466

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Becaplermin
Description: 0.25 cm of 100 µg/g Becaplermin gel topically per 1cm² of ulcer area applied 3 times per week for 6 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Becaplermin
Description: 0.25 cm of 100 µg/g Becaplermin gel topically per 1cm² of ulcer area applied 3 times per week for 6 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Promagran Dressing
Description: 44% oxidized regenerated cellulose (ORC), 55% collagen and 1% silver-ORC wound dressing applied 3 times per week for 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Dressing
Description: Inactive wound dressing.
Study: NCT01262963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: A single oral dose of 95 mg of GSK2118436 containing approximately 80 µCi of radioactivity
Study: NCT01596231

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Kudzu
Description: Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session to see if it will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a pretreatment 2 ½ hours before a drinking session
Study: NCT03676413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals
Description: new generic product of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder twice daily inhalation throughout the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK
Description: twice daily inhalation throughout the study
Study: NCT03940638

Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study: NCT01843673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo FBCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cone-beam computed tomography
Description: Undergo dual CBCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiography
Description: Undergo 2-D x-ray with Varian kV OBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiography
Description: Undergo 2-D x-ray with Brain Lab ExacTrac

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiography
Description: Undergo 2-D x-ray with Varian MV OBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electronic portal imaging
Description: Undergo EPID imaging

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: image-guided adaptive radiation therapy
Description: Undergo IGART
Study: NCT02321319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone HCl ER Tablets
Description: Hydromorphone hydrochloride (HCl) extended release tablet
Study: NCT03186443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin was taken 300mg,q 12h for 6 month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin was taken 0.4, tid for 6 month.
Study: NCT03676413

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily inhalation throughout the study
Study: NCT03790215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Description: The investigators give participants oral dydrogesterone(as described in arm description).After 3 cycles of treatment, the investigators evaluate the treatment effects.
Study: NCT03951142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: This trial is open-label; therefore, the participant, the trial site personnel, the Sponsor and/or designee are not blinded to treatment. Drug identity (name, strength) is included in the label text. Storage, handling and preparation requirements will be handled in concordance with the Pharmacy Manual for losartan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: This trial is open-label; therefore, the participant, the trial site personnel, the Sponsor and/or designee are not blinded to treatment. Drug identity (name, strength) is included in the label text. Storage, handling and preparation requirements will be handled in concordance with the Pharmacy Manual for losartan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: This trial is open-label; therefore, the participant, the trial site personnel, the Sponsor and/or designee are not blinded to treatment. Drug identity (name, strength) is included in the label text. Storage, handling and preparation requirements will be handled in concordance with the Pharmacy Manual for losartan.
Study: NCT04148170

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endodiathermy Probe and Intubation Versus Intubation
Description: children suffer from congenital nasolacrimal duct obstruction will have probing with endodiathermy probe and then intubation with bicanlicular silicon tube
Study: NCT06029868

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black seed oil capsule
Description: 700 mg black seed soft gel capsule once a day from Gorgan Essential Oil Pharmaceutical Company,

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Black seed oil capsule
Description: Placebo Black seed oil capsule
Study: NCT04452058

Intervention type: OTHER
Intervention: Radiomic Algorithm
Description: Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction

Intervention type: OTHER
Intervention: Radiomic Algorithm
Description: Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction

Intervention type: OTHER
Intervention: Radiomic Algorithm
Description: Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction

Intervention type: OTHER
Intervention: Radiomic Algorithm
Description: Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction
Study: NCT01805219

Intervention type: OTHER
Intervention: GPS and accelerometer recording (s) during exercises
Study: NCT02894554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telbivudine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lamivudine
Study: NCT02919787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Neoadjuvant treatment
Study: NCT02708121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Intervention
Description: Participants complete web-based assessment and receive tailored feedback to motivate weight loss treatment initiation and informed that they have access to weight loss treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator Intervention
Description: Participants informed that they have access to weight loss treatment.
Study: NCT02919787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatine
Description: Neoadjuvant treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Neoadjuvant treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatic surgery
Description: All patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic surgery
Description: All patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Adjuvant treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: Adjuvant treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatine
Description: Adjuvant treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatine
Description: Adjuvant treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Adjuvant treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Adjuvant treatment
Study: NCT03986840

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: A multicomponent exercise program
Study: NCT03211611

Intervention type: BEHAVIORAL
Intervention: Questionnaire given to the two groups
Description: Questionnaire given to the two groups :~Patients with BRCA ½ mutation GP

Intervention type: BEHAVIORAL
Intervention: Questionnaire given to the two groups
Description: Questionnaire given to the two groups :~Patients with BRCA ½ mutation GP
Study: NCT00582543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eMRI/MRSI
Description: Patients will undergo eMRI/MRSI examination. All subjects will be asked to administer a Fleet enema on the day of the study in order to reduce the potential for fecal residue to interfere with imaging acquisition and quality. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position. The entire eMRI/MRSI study will be performed within 55-60 minutes.
Study: NCT02739386

Intervention type: BIOLOGICAL
Intervention: Ipilimumab
Description: Intravenous monoclonal antibody injection
Study: NCT02668588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release of octreotide
Description: 1 intramuscular injection of extended release of octreotide 30 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: extended release of placebo
Description: 1 intramuscular injection of extended release of placebo
Study: NCT00927732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroquinidine
Description: capsules of 300 mg LP, 1 or 2 or 3 times per day : frequency will be determined by tests after patient inclusion before her/his randomization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (sugar)
Description: capsules of placebo have same design and color than capsules of hydroquinidine except for their content as they contain sugar and not hydroquinidine
Study: NCT01005277

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04241315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTL38 for Injection
Description: Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL

Intervention type: DRUG
Group type: OTHER
Intervention: OTL38 for Injection
Description: Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near infrared camera imaging system
Description: Near infrared camera imaging system
Study: NCT00872794

Intervention type: DEVICE
Group type: OTHER
Intervention: DePuy ASR™ Hip System
Description: A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
Study: NCT03429010

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New guideline anesthesia strategy team
Description: New guideline anesthesia strategy team
Study: NCT03421795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Let's Talk About Pain Training
Description: See arm/group descriptions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Family Centered Care Training
Description: See arm/group descriptions.
Study: NCT00822627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Influenza Vaccination
Description: 0.5 mL Sanofi-Pasteur intramuscular influenza vaccination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and referral
Description: Patients are given information regarding the inactivated influenza vaccination and a list of community providers who provide influenza vaccination
Study: NCT02301546

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: computerized cognitive exercises
Description: Each group will perform computerized cognitive exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks. The experimental group will use exercises shown to improve cognition, whereas the comparator group will use exercises without clear beneficial findings.
Study: NCT03986840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: A multicomponent exercise program
Study: NCT02301546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computerized cognitive exercises
Description: Each group will perform computerized cognitive exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks. The experimental group will use exercises shown to improve cognition, whereas the comparator group will use exercises without clear beneficial findings.